secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2025-11-20T23:59:59+00:00
Accession:  0001104659-25-114422
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott to acquire Exact Sciences for $105/share, total equity value ~$21B
-------------------------------------------------------------------------

- Abbot buys Exact Sciences for $105 per share in cash; equity value ~$21B, enterprise value ~$23B.
- Exact Sciences 2025 revenue >$3B with high-teens organic growth; adds cancer diagnostics vertical.
- Close expected Q2 2026, subject to Exact Sciences shareholder vote and regulatory approvals (incl. HSR).
- Immediately accretive to Abbott's revenue growth (+50bps Abbott, +300bps Diagnostics) and gross margin (+100bps).
- Financing via cash and up to $20B bridge loan from Morgan Stanley; initial 2026 debt/EBITDA ~2.7x.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000110465925114422/0001104659-25-114422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000110465925114422/tm2531676d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-114422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer